Medici Bianca, Benatti Stefania, Dominici Massimo, Gelsomino Fabio
Department of Medical and Surgical Sciences for Children and Adults, Division of Oncology, University Hospital of Modena, 41124 Modena, Italy.
Int J Mol Sci. 2025 May 30;26(11):5268. doi: 10.3390/ijms26115268.
Metastatic colorectal cancer (mCRC) remains a major cause of cancer-related mortality worldwide and requires the development of new biomarkers to improve patient management. Traditional markers, such as RAS mutations and microsatellite instability (MSI), have revolutionized therapeutic decisions, but emerging evidence underlines the importance of integrating multi-omics sciences for a deeper understanding of tumor biology and therapeutic resistance. Although these omics technologies hold great promise for the advancement of precision oncology, significant challenges remain. However, the integration of multi-omics data is opening the way to more accurate diagnostics, personalized therapies, and improved outcomes for mCRC patients. This review provides an in-depth description of the various omics sciences and explores their advantages and critical issues.
转移性结直肠癌（mCRC）仍是全球癌症相关死亡的主要原因，需要开发新的生物标志物以改善患者管理。传统标志物，如RAS突变和微卫星不稳定性（MSI），已经彻底改变了治疗决策，但新出现的证据强调了整合多组学科学对于更深入理解肿瘤生物学和治疗耐药性的重要性。尽管这些组学技术在精准肿瘤学的发展中具有巨大潜力，但重大挑战依然存在。然而，多组学数据的整合正在为mCRC患者带来更准确的诊断、个性化治疗和更好的治疗效果。本综述深入描述了各种组学科学，并探讨了它们的优势和关键问题。
